Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q1 2025 · 10-Q
Revenue—
Net Income-$632.85K-$632.85KN/M vs Q1 2024 EPS Diluted$0.00$0.00— vs Q1 2024 Operating Income-$674,551N/M Operating Cash Flow-$1,284,969N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 14, 2025 · 44 d after period end